Skip to main content

anti-cd19-glucosteroid receptor modulator adc abbv-31

Generic: Anti-CD19-Glucosteroid Receptor Modulator ADC ABBV-31

anti-cd19-glucosteroid receptor modulator adc abbv-31: 2 clinical trials tracked.

anti-cd19-glucosteroid receptor modulator adc abbv-31 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-cd19-glucosteroid receptor modulator adc abbv-31, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence4 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase1b, Multiple Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Safety, and Efficacy of ABBV-319 in Subjects With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724Registry updated 2026-08-10·Phase 1·ABBV
Recruiting

Primary endpoint: Number of Participants with Adverse Events (AEs)

Interventionalopen36 targetStarted 2025-08Completion 2029-0311 sites · France, Netherlands, United StatesAbbVie

A First In Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

NCT05512390Registry updated 2026-08-28·Phase 1·ABBV
Active, not recruiting

Primary endpoint: Number of Dose-Limiting Toxicities (DLT)

Interventionalopen39 enrolledStarted 2023-04Completion 2027-0220 sites · Australia, Canada, Israel, South Korea…AbbVie